Stephen J Ralis

Array ( [id] => 12212100 [patent_doc_number] => 09908892 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-06 [patent_title] => 'Melampomagnolide B derivatives' [patent_app_type] => utility [patent_app_number] => 15/254849 [patent_app_country] => US [patent_app_date] => 2016-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 55107 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15254849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12247297 [patent_doc_number] => 09920063 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Melampomagnolide B derivatives' [patent_app_type] => utility [patent_app_number] => 15/251889 [patent_app_country] => US [patent_app_date] => 2016-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 30 [patent_no_of_words] => 36924 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15251889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15420597 [patent_doc_number] => 10543200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Compositions and methods for drug sensitization of parasites [patent_app_type] => utility [patent_app_number] => 15/754244 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 10621 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 349 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15754244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15751073 [patent_doc_number] => 10617616 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Cosmetic composition comprising a salicylic acid compound [patent_app_type] => utility [patent_app_number] => 15/755850 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6206 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 236 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15755850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13942309 [patent_doc_number] => 10206899 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Method for removing bacterial biofilms [patent_app_type] => utility [patent_app_number] => 15/247455 [patent_app_country] => US [patent_app_date] => 2016-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4509 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15247455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11335563 [patent_doc_number] => 20160361319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION' [patent_app_type] => utility [patent_app_number] => 15/247518 [patent_app_country] => US [patent_app_date] => 2016-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 24751 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15247518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14482613 [patent_doc_number] => 10328065 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer [patent_app_type] => utility [patent_app_number] => 15/755122 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11865 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15755122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618390 [patent_doc_number] => 20170128577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'SURFACE MODIFIED NANOCRYSTALLINE CELLULOSE AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/245883 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4827 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15245883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14482615 [patent_doc_number] => 10328066 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer [patent_app_type] => utility [patent_app_number] => 15/755140 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10885 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15755140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11441786 [patent_doc_number] => 20170042807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON' [patent_app_type] => utility [patent_app_number] => 15/240485 [patent_app_country] => US [patent_app_date] => 2016-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4215 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15240485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13885277 [patent_doc_number] => 10195170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs [patent_app_type] => utility [patent_app_number] => 15/238950 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 3386 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15238950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14085491 [patent_doc_number] => 10238625 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-26 [patent_title] => Methods for the treatment of mast cell related disorders with mast cell stabilizers [patent_app_type] => utility [patent_app_number] => 15/750809 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59459 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14196421 [patent_doc_number] => 10265296 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-23 [patent_title] => Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders [patent_app_type] => utility [patent_app_number] => 15/750811 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59202 [patent_no_of_claims] => 54 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790917 [patent_doc_number] => 20190008997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => LARGE 3D POROUS SCAFFOLDS MADE OF ACTIVE HYDROXYAPATITE OBTAINED BY BIOMORPHIC TRANSFORMATION OF NATURAL STRUCTURES AND PROCESS FOR OBTAINING THEM [patent_app_type] => utility [patent_app_number] => 15/750568 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11589662 [patent_doc_number] => 20170114074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE' [patent_app_type] => utility [patent_app_number] => 15/226705 [patent_app_country] => US [patent_app_date] => 2016-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22740 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15226705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12036520 [patent_doc_number] => 09814732 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-14 [patent_title] => 'Ulipristal acetate for prevention and treatment of breast tumors' [patent_app_type] => utility [patent_app_number] => 15/223066 [patent_app_country] => US [patent_app_date] => 2016-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 6891 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15223066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11269192 [patent_doc_number] => 20160331739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS' [patent_app_type] => utility [patent_app_number] => 15/218670 [patent_app_country] => US [patent_app_date] => 2016-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10392 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15218670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13353225 [patent_doc_number] => 20180228152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => DISPERSED LACTAMS [patent_app_type] => utility [patent_app_number] => 15/750895 [patent_app_country] => US [patent_app_date] => 2016-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11120466 [patent_doc_number] => 20160317440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON' [patent_app_type] => utility [patent_app_number] => 15/209995 [patent_app_country] => US [patent_app_date] => 2016-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4177 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15209995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393862 [patent_doc_number] => 20170014397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'IRON CHELATORS FOR TREATING AND PREVENTING CELL DEATH AND ORGAN DAMAGE FOLLOWING AN ISCHEMIC EVENT' [patent_app_type] => utility [patent_app_number] => 15/209261 [patent_app_country] => US [patent_app_date] => 2016-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 18612 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15209261 [rel_patent_id] =>[rel_patent_doc_number] =>)